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Abstract 
 
Estimation of the cancer cell fraction in breast cancer tissue is important for exclusion of 
samples unsuitable for multigene prognostic assays and a variety of molecular analyses 
for research. Here, we aimed to establish a breast cancer cell fraction marker based on 
DNA methylation. First, we screened genes unmethylated in non-cancerous mammary 
tissues and methylated in breast cancer tissues using microarray data from the TCGA 
database, and isolated 12 genes. Among them, four genes were selected as candidate 
marker genes without a high incidence of copy number alterations and with broad 
coverage across patients. Bisulfite pyrosequencing analysis of additional breast cancer 
biopsy specimens purified by laser capture microdissection (LCM) excluded two genes, 
and a combination of SIM1 and CCDC181 was finally selected as a fraction marker. In 
further additional specimens without LCM purification, the fraction marker was 
substantially methylated (≥ 20%) with high incidence (50/51). The cancer cell fraction 
estimated by the fraction marker was significantly correlated with that estimated by 
microscopic examination (p < 0.0001). Performance of a previously established marker, 
HSD17B4 methylation, which predicts therapeutic response of HER2-positive breast 
cancer to trastuzumab, was improved after the correction of cancer cell fraction by the 
fraction marker. In conclusion, we successfully established a breast cancer cell fraction 
marker based on DNA methylation.  
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Introduction 
 
Accurate molecular analyses of cancer tissues, such as genomic sequencing, gene 
expression analysis, and epigenetic analysis, can be achieved by taking account of co-
existing non-cancerous cells in the cancer tissues [1-4]. A gold standard method to 
estimate a cancer cell fraction is microscopic cell counting using pathological sections. 
However, this method is time-consuming, and distinction of cancer cells from co-existing 
non-cancerous cells is sometimes difficult. To overcome this issue, we established a 
method to estimate the cancer cell fraction in DNA samples based on DNA methylation 
[5, 6]. Since DNA methylation patterns are specific to individual cell types [7-13], the 
cancer cell fraction can be estimated using a small number of genes specifically 
methylated in cancer cells, not in non-cancerous cells [5]. Because the analysis is 
conducted using DNA samples, histological sections are unnecessary for this method.  
In breast cancer, extensive molecular analyses, including multigene prognostic assays 
such as Oncotype DX or MammaPrint, are conducted for clinical practice and research. 
In the multigene prognostic assays, samples with a low cancer cell fraction must be 
excluded [14, 15]. Among various research, for example, HSD17B4 methylation predicts 
pathological complete response (pCR) in patients with HER2-positive breast cancer after 
trastuzumab therapy [16]. For this prediction, the HSD17B4 methylation levels need to 
be corrected by the cancer cell fraction using microscopic examination. Thus, once we 
can establish the cancer cell fraction in breast cancer, it is expected to reduce the workload 
of pathologists.  
In this study, we aimed to establish a DNA methylation marker to estimate breast 
cancer cell fractions.   
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Materials and methods 
 
Breast cancer biopsy specimens and blood samples 
Most of the breast cancer specimens (58 of 61) were obtained from our previous study 
[16], and the remaining three were newly obtained. The clinical study, along with this 
exploratory study, was approved by the National Cancer Center Ethics Committee 
(approval no. 2010-250), and was registered at the UMIN Clinical Trial Registry 
(Registration no. UMIN000007074). Written informed consents were obtained from all 
participants. All the 61 specimens were collected by needle biopsy from 61 patients with 
a diagnosis of HER2-positive breast cancer (Supplementary Table 1). The specimens 
were fixed using the PAXgene Tissue System (Qiagen, Hilden, Germany) and embedded 
in low-melting paraffin for DNA extraction using 10 slices of 10 µm sections. A certified 
and experienced pathologist (S.F.) conducted microscopic examination of the specimens 
to determine the cancer cell fraction. The pathological complete response (pCR) to 
trastuzumab was defined as no residual cancer cells in the specimens according to the 
system of American Joint Committee on Cancer. Among the 61 specimens, 10 specimens 
were purified by laser capture microdissection (LCM). Three peripheral leucocyte 
samples were obtained from three healthy volunteers. 
 
Breast cancer cell lines and human mammary epithelial cells 
A total of 20 human breast cancer cell lines (BT-474, SK-BR-3, MDA-MB-453, 
HCC38, MDA-MB-231, T-47D, Hs 578T, MCF7, UACC-3199, ZR-75-1, BT-20, MDA-
MB-436, HCC1937, MDA-MB-468, HCC1428, BT-549, AU565, HCC1395, MDA-MB-
157, and HCC1954) were purchased from the American Type Culture Collection 
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(Rockville, MD). Human Mammary Epithelial Cells (HMECs) were purchased from 
Cambrex (East Rutherford, NJ).  
 
Genome-wide DNA methylation analysis 
Genome-wide DNA methylation analysis of HMECs, peripheral leucocyte samples, 
and breast cancer cell lines was conducted using an Infinium HumanMethylation450 
BeadChip array (Illumina, San Diego, CA, USA), as previously reported [17]. 
Additionally, we downloaded HumanMethylation450 data of 27 breast cancer tissues and 
15 non-cancerous mammary tissues randomly from the 1,234 breast tissue samples 
registered in the TCGA database (Supplementary Table 2). The DNA methylation level 
of an individual probe was obtained as a β value that ranged from 0 (unmethylated) to 1 
(fully methylated). From all of 482,421 probes located on CpG sites, we excluded 5,077 
probes at genomic positions that could not be identified according to the human genome 
assembly hg38. The remaining 477,344 probes on autosomes and sex chromosomes were 
evaluated in this study.  
 
Measurement of DNA methylation levels of specific genomic regions  
Gene-specific DNA methylation levels were analyzed by bisulfite pyrosequencing. 
Specifically, bisulfite modification was conducted using 1 µg of BamHI-digested 
genomic DNA, as previously reported [18]. The modified DNA was suspended in 40 µl 
of TE buffer, and an aliquot of 1 µl was used for bisulfite pyrosequencing [19]. A target 
genomic region was amplified by biotinylated primers. The PCR product labelled with 
biotin was annealed to a 0.2 µM pyrosequencing primer, and pyrosequencing was carried 
out using the PSQ 96 Pyrosequencing System (QIAGEN, Valencia, CA, USA). The 
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methylation level was obtained using PSQ Assay Design software (QIAGEN). 
 
Correction of HSD17B4 methylation level by the breast cancer cell fraction 
The methylation level of HSD17B4 was corrected by the breast cancer cell fraction 
estimated by a fraction marker or by microscopic examination as follows: [Corrected 
HSD17B4 methylation level = 100 × (HSD17B4 methylation level)/ (a cancer cell 
fraction)].  
 
Statistical analysis 
The correlation analysis was performed using the Pearson’s product-moment 
correlation coefficients. Differences in corrected methylation level of HSD17B4 between 
trastuzumab responders (pCR specimens) and non-responders (non-pCR specimens) 
were evaluated by the Mann–Whitney U test. All the analyses were performed using 
PASW statistics version 18.0 (SPSS Japan Inc., Tokyo, Japan), and two-sided p-values < 
0.05 were considered statistically significant.  
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Results 
 
Isolation of genomic regions specifically methylated in breast cancer cells 
To isolate genomic regions specifically methylated in breast cancer cells, we first 
selected 136,830 probes unmethylated (β value ≤ 0.2) in the non-cancerous mammary 
cells (HMECs, peripheral leucocyte samples, and non-cancerous mammary tissues) from 
the 477,344 probes located on autosomes and sex chromosomes (Figure 1). From the 
136,830 probes, we then selected 475 probes methylated in 20 breast cancer cell lines (β 
≥ 0.8; ≥ 8/20 cell lines) and 27 cancer tissues (β ≥ 0.3; ≥ 21/27 tissues). We further selected 
39 probes from 10 genomic regions (9 genes) that had multiple (≥ 3) flanking probes with 
consistent values [20, 21]. Alternatively, from the 136,830 probes, we isolated 93 probes 
more frequently methylated both in cancer cell lines (≥ 16/20) and cancer tissues (≥ 21/27). 
We further selected 12 probes from 6 genomic regions (3 genes) that had multiple (≥ 2) 
flanking probes with consistent values. Collectively, a total of 12 genes was isolated as 
candidate marker genes (Supplementary Table 3). 
For the 12 genes, we further evaluated copy number alterations (CNAs) in breast 
cancer because CNAs could affect the estimation of cancer cell fraction based on the DNA 
methylation levels [5, 22] (Supplementary Table 3). After the exclusion of one gene with 
a high incidence of CNAs in breast cancer (≥ 3%) [23], the remaining 11 genes were 
considered to have minimum influence of CNAs on the estimation of the cancer cell 
fraction.    
 
Selection of a panel of genes with broad coverage across patients  
To identify candidate marker genes methylated in different groups of patients, we 
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conducted a hierarchical clustering analysis of the 27 breast cancer tissues used for the 
screening and 48 probes in the 11 candidate marker genes (Supplementary Table 3). The 
samples were separated into three major clusters, and the probes into four second-level 
clusters (I, II, III, and IV clusters) (Figure 2). From each of the four second-level clusters, 
we searched for genes that had broad coverage across the samples and for which high-
quality primers for bisulfite pyrosequencing could be designed. Consequently, we 
selected four genes, namely, SYCN, MIR129-2, SIM1, and CCDC181 (Table 1 and Figure 
3), with high-quality primers (Supplementary Table 4). The four genes covered different 
groups of patients and collectively had different coverage of patients and breast cancer 
cell lines (Supplementary Figure 1). 
 
Methylation levels in breast cancer biopsy specimens 
To evaluate whether the four candidate marker genes could estimate the breast cancer 
cell fraction, methylation levels of the four genes were analyzed by bisulfite 
pyrosequencing in 10 breast cancer biopsy specimens purified by LCM (Supplementary 
Figure 2). SYCN was methylated (≥ 20%), even in LCM-purified non-cancerous cells, too 
frequently (BC53s, BC57s, BC59s, BC60s, and BC61s), and was excluded from the 
candidate marker genes. Among the remaining three genes, MIR129-2 showed 
consistently lower methylation levels than SIM1 and CCDC181 in LCM-purified cancer 
cells, and was excluded. Resultantly, we adopted the remaining two genes, SIM1 and 
CCDC181, as final candidate marker genes (Figure 4A).  
The methylation levels of the two genes were then analyzed in an additional 51 
specimens without LCM purification. Substantial methylation levels (≥ 20%) of at least 
one of SIM1 and CCDC181 were observed in 50 specimens (98.0%) (Figure 4B). 
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Therefore, when we adopted a higher methylation level of the two genes, their 
combination was considered to be capable of estimating breast cancer cell fractions with 
broad coverage across patients.  
 
Correlation between the cancer cell fraction estimated by the final candidate marker 
genes and that estimated by microscopic examination 
To assess how accurately the cancer cell fraction could be estimated by the two marker 
genes, we evaluated the correlation between the cancer cell fractions estimated by the two 
genes and that estimated by microscopic examination in the 61 breast cancer biopsy 
specimens, including the 10 specimens with LCM purification and the 51 specimens 
without LCM purification (Figure 5). We obtained a significant correlation between the 
cancer cell fractions estimated by the two methods (R = 0.48, p < 0.0001). Therefore, the 
combination of the two genes was considered as a marker that could estimate breast 
cancer cell fractions.  
 
Application of the cancer cell fraction marker to the correction of HSD17B4 
methylation levels  
Finally, we evaluated how the cancer cell fraction marker could correct HSD17B4 
methylation levels by estimating the cancer cell fraction and improve the sensitivity and 
specificity of HSD17B4 methylation. For this purpose, we used the 61 breast cancer 
biopsy specimens in which the pCR was observed in 22 specimens (36.1%). Based upon 
the raw methylation data, no significant difference of the HSD17B4 methylation levels 
was observed between pCR and non-pCR specimens (p = 0.245) (Figure 6). In contrast, 
after the correction, the methylation level was significantly higher in the pCR specimens 
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than in the non-pCR specimens (microscopic examination: p = 0.0001; fraction marker: 
p = 0.0004). Regarding the sensitivity and specificity to predict pCR (Table 2), it was 
13.6 % and 94.9 %, respectively, before the correction. Those after the correction by the 
DNA methylation marker (59.1 % and 84.6 %) were equivalent to those corrected by 
microscopic examination (59.1% and 87.2%).   
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Discussion  
 
We successfully established a DNA methylation marker using two genes, SIM1 and 
CCDC181, which could estimate the breast cancer cell fraction in DNA samples. The 
cancer cell fraction estimated by the DNA methylation marker was significantly 
correlated with that estimated by microscopic examination. In addition, the performance 
of the HSD17B4 methylation to predict pCR was improved after the correction of the 
cancer cell fraction by the fraction marker to the same degree by the correction using 
microscopic examination. These findings demonstrated that the DNA methylation marker 
could be applied to correct the cancer cell fraction in breast cancer.   
The estimation of cancer cell fractions using a DNA methylation marker has several 
advantages. Firstly, DNA methylation can be analyzed using DNA samples without the 
need for histological sections. Secondly, the DNA methylation marker can not only save 
pathologists' labor in microscopic cell counting but also improve the quality of estimation 
of the cancer cell fraction. In histological analysis, only the first or last section of a 
paraffin-embedded tissue block is stained and used for microscopic cell counting. 
However, for the middle sections, the cells are not counted, and it results in an 
unavoidable error in the estimation of the cancer cell fraction. Thirdly, quantitative 
methylation analysis is more cost-effective compared with single nucleotide 
polymorphism microarray or next-generation sequencing, which are other molecular 
technologies to estimate cancer cell fractions [24, 25].   
Unexpectedly, we observed that the fraction marker genes had low-level methylation 
even in the LCM-purified non-cancerous cells. This methylation might be caused by 
contaminating cancer cells. However, its possibility was considered to be low because the 
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low-level methylation was observed too frequently (nine of 10 specimens) as a 
contamination. Alternatively, the low-level methylation could be due to accumulation of 
aberrant methylation in normal appearing cells, predisposing them to carcinogenesis (i.e., 
field cancerization) [26, 27]. It is well established in other cancers, such as gastrointestinal 
cancers, that non-cancerous cells can have aberrant DNA methylation and that the degree 
of aberrant DNA methylation is correlated with a cancer risk [28-30]. To use the DNA 
methylation marker established here, we should note a risk of overestimation of the cancer 
cell fraction in low methylation ranges.   
In conclusion, we established a DNA methylation marker to estimate breast cancer 
cell fractions in DNA samples. We expect that this marker will be useful in many aspects 
of molecular analyses of breast cancers.  
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Figure legends  
 
Figure 1. Isolation flow of genomic regions specifically methylated in breast cancer 
cells using genome-wide DNA methylation data 
The genome-wide DNA methylation data were obtained from i) our own analysis of 
HMECs, peripheral leucocyte samples, and breast cancer cell lines, and ii) the TCGA 
database of breast cancer tissues and non-cancerous mammary tissues. Probes 
unmethylated in non-cancerous mammary cells were isolated using the criteria in the 
Figure, and then those methylated in breast cancer cells were isolated using three-
consecutive- and two-consecutive-probe approaches. Isolated candidate probes were 
assembled into genes, and 12 genes were finally isolated as candidate marker genes. 
 
Figure 2. Selection of a panel of marker genes with a broad coverage 
A hierarchical clustering analysis of the 27 breast cancer tissues used for the screening 
was conducted using 48 probes in the 11 candidate marker genes. From the four second-
level clusters (I, II, III and IV; shown by bars on the left side), four genes with high-
quality primers for bisulfite pyrosequencing, SYCN (probe ID: cg02863073), MIR129-2 
(cg14416371), SIM1 (cg27252696), and CCDC181 (cg24808280), were selected for 
further analysis.  
 
Figure 3. Genomic structure of the four candidate marker genes 
Gene structure and location of a CpG island are shown at the top. A CpG map around the 
target CpG sites is shown in the bottom. Vertical lines show individual CpG sites. Arrows 
show the locations of probes in the microarray. A triangle shows the CpG site analyzed 
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by bisulfite pyrosequencing.  
 
Figure 4. Methylation levels of SIM1 and CCDC181 in breast cancer biopsy 
specimens 
Methylation levels of SIM1 and CCDC181 were analyzed by bisulfite pyrosequencing. 
(A) The analysis of 10 breast cancer biopsy specimens with LCM purification showed 
that at least one of the two genes was specifically methylated in LCM-purified cancer 
cells. (B) The analysis of an additional 51 specimens without LCM purification showed 
that substantial methylation levels (≥ 20%) of at least one of the two genes were observed 
in 50 of 51 [98.0%] specimens (except for BC24).  
 
Figure 5. Correlation between the cancer cell fraction estimated by the SIM1 and 
CCDC181 and that estimated by microscopic examination  
There was a significant correlation between the cancer cell fraction estimated by the two 
genes (SIM1 and CCDC181) and that estimated by microscopic examination (R = 0.48, p 
< 0.0001).  
 
Figure 6. Predictive performance of the HSD17B4 methylation after the correction 
of cancer cell fraction  
The HSD17B4 methylation level was corrected by the breast cancer cell fraction 
estimated by microscopic examination and by the fraction marker. HSD17B4 methylation 
was significantly higher in pCR specimens compared to that in non-pCR specimens 
(microscopic examination: p = 0.0001; fraction marker: p = 0.0004).   
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Supplementary Figure legends  
 
Supplementary Figure 1. The coverage of breast cancer tissues and cell lines by the 
four candidate marker genes.  
The four candidate marker genes, SYCN, MIR129-2, SIM1, and CCDC181, had broad and 
different coverage groups of (A) breast cancer tissues and (B) cancer cell lines. Red and 
blue cells show samples with β values ≥ 0.3 and ≥ 0.8, respectively. A black cell shows a 
gene without signals. Samples and cell lines from HER2-positive breast cancer are shown 
by asterisks.  
 
Supplementary Figure 2. Individual methylation levels of the four candidate marker 
genes in 10 LCM-purified breast cancer biopsy specimens   
Individual methylation levels of the four candidate genes, SYCN, MIR129-2, SIM1, and 
CCDC181, in 10 LCM-purified breast cancer biopsy specimens are shown. SYCN was 
excluded from the candidates because of its high frequency of methylation (≥ 20%) even 
in LCM-purified non-cancerous cells (BC53s, BC57s, BC59s, BC60s, and BC61s). 
MIR129-2 was also excluded because its methylation levels were consistently lower than 
those of SIM1 and CCDC181 in LCM-purified cancer cells. Resultantly, the remaining 
two genes, SIM1 and CCDC181, were adopted as final candidate marker genes. 
 
Table 1. Candidate genomic regions for a breast cancer cell fraction marker 
 
No. Gene 
symbol 
Chr Nt number Probe ID Relation to a 
CpG island 
Position to a TSS    No. of 
consecutive 
probes 
Incidence of 
methylation in 
cancer cell lines 
Incidence of 
methylation in 
cancer tissues 
1 SYCN 19 39204191 cg02863073 Island 76 2 16/20 21/27 
2 MIR129-2 11 43581297 cg14416371 Island 24860;2407;1801;-
84 
3 12/20 23/27 
3 SIM1 6 100465064 cg27252696 Island -1386;-134;-174 3 12/20 21/27 
4 CCDC181 1 169427630 cg24808280 Island -155;-212;-167;-
155;33040 
3 13/20 24/27 
Genomic location was based upon human genome assembly hg38. Chr, chromosome; Nt, nucleotide; TSS, transcriptional start site 
  
Table 2. Predictive performance of HSD17B4 methylation before and after the correction by microscopic examination and by the 
methylation fraction marker 
 
  HSD17B4 
methylation 
# of samples with 
pCR 
# of samples with 
non-pCR 
Sensitivity 
(%) 
Specificity 
(%) 
Positive predictive 
value (%) 
No correction High 3 2 13.6 94.9 60 
 Low 19 37    
Correted by       
 microscopic 
examination 
High 13 5 59.1 87.2 72.2 
 Low 9 34    
       
 methylation 
fraction marker 
High 13 6 59.1 84.6 68.4 
  Low 9 33       
HSD17B4 methylation levels were divided into high and low using a cutoff value of 50 % previously established [16]. pCR, pathological 
complete response 
Patient ID Esterogen receptorstatus
Progesteron receptor
status
HER2 receptor
status Pathological diagnosis
Clinical
stage
LCM-
purification
Therapeutic response
to trastuzumab
In the previous
study*
BC01 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified pCR Used
BC02 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC03 Positive Positive Positive Invasive lobular carcinoma IIB Non-purified Non-pCR Used
BC04 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC05 Positive Negative Positive Invasive ductal carcinoma IIIC Non-purified Non-pCR Used
BC06 Negative Negative Positive Invasive ductal carcinoma IIIA Non-purified pCR Not used
BC07 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified pCR Used
BC08 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified pCR Used
BC09 Positive Positive Positive Invasive ductal carcinoma IIIA Non-purified Non-pCR Used
BC10 Negative Positive Positive Invasive ductal carcinoma IIB Non-purified pCR Used
BC11 Positive Negative Positive Invasive ductal carcinoma IIIA Non-purified Non-pCR Used
BC12 Negative Negative Positive Invasive ductal carcinoma IIIA Non-purified pCR Used
BC13 Negative Negative Positive Invasive ductal carcinoma IIIC Non-purified pCR Used
BC14 Positive Positive Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC15 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified pCR Used
BC16 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC17 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC18 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC19 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC20 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified pCR Used
BC21 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified pCR Used
BC22 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Not used
BC23 Negative Negative Positive Apocrine carcinoma IIA Non-purified pCR Used
BC24 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC25 Positive Positive Positive Invasive lobular carcinoma IIA Non-purified Non-pCR Used
BC26 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC27 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC28 Positive Positive Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC29 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC30 Positive Positive Positive Invasive ductal carcinoma IIIC Non-purified Non-pCR Used
BC31 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC32 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC33 Negative Negative Positive Invasive ductal carcinoma IIIC Non-purified pCR Used
BC34 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC35 Positive Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC36 Positive Positive Positive Invasive ductal carcinoma IIB Non-purified pCR Used
BC37 Positive Positive Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC38 Positive Positive Positive Invasive ductal carcinoma IIIC Non-purified Non-pCR Used
BC39 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC40 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified Non-pCR Used
BC41 Negative Negative Positive Invasive ductal carcinoma IIIA Non-purified Non-pCR Used
BC42 Negative Negative Positive Medullary carcinoma IIA Non-purified Non-pCR Used
BC43 Positive Negative Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC44 Negative Negative Positive Invasive lobular carcinoma IIIA Non-purified pCR Used
BC45 Positive Negative Positive Invasive ductal carcinoma IIIC Non-purified pCR Used
BC46 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC47 Positive Positive Positive Invasive ductal carcinoma IIIA Non-purified Non-pCR Used
BC48 Negative Negative Positive Invasive ductal carcinoma IIIA Non-purified Non-pCR Used
BC49 Positive Positive Positive Invasive ductal carcinoma IIA Non-purified Non-pCR Used
BC50 Negative Negative Positive Invasive ductal carcinoma IIA Non-purified pCR Used
BC51 Negative Negative Positive Invasive ductal carcinoma IIB Non-purified pCR Used
BC52 Negative Negative Positive Invasive ductal carcinoma IIB Purified pCR Used
BC53 Negative Negative Positive Invasive ductal carcinoma IIB Purified Non-pCR Used
BC54 Negative Negative Positive Invasive ductal carcinoma IIB Purified Non-pCR Used
BC55 Negative Negative Positive Invasive ductal carcinoma IIIA Purified Non-pCR Used
BC56 Negative Negative Positive Invasive ductal carcinoma IIB Purified pCR Used
BC57 Negative Negative Positive Invasive ductal carcinoma IIB Purified pCR Used
BC58 Negative Negative Positive Invasive ductal carcinoma IIA Purified pCR Used
BC59 Positive Positive Positive Invasive ductal carcinoma IIB Purified Non-pCR Used
BC60 Positive Positive Positive Invasive ductal carcinoma IIA Purified pCR Not used
BC61 Positive Positive Positive Invasive ductal carcinoma IIA Purified Non-pCR Used
* Used in the previous study with reference number [16]. LCM, laser capture microdissection
Supplementary Table 1. Patient background of breast cancer biopsy specimens
TCGA biospecimen ID Sample Sample ID Esterogenreceptor status
Progesteron
receptor status
HER2 receptor
status Pathological diagnosis
Pathological
Stage Age
TCGA-AR-A1AM Cancer tissue TBC01 Positive Positive Negative Infiltrating Lobular Carcinoma IIIA 52
TCGA-OL-A6VQ Cancer tissue TBC02 Positive Positive Negative Infiltrating Lobular Carcinoma IIA 49
TCGA-A2-A1G1 Cancer tissue TBC03 Negative Negative Positive Infiltrating Ductal Carcinoma IIB 85
TCGA-AR-A24X Cancer tissue TBC04 Positive Positive Negative Mixed Histology IIA 52
TCGA-D8-A1Y3 Cancer tissue TBC05 Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 61
TCGA-BH-A0H7 Cancer tissue TBC06 Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 65
TCGA-A7-A13F Cancer tissue TBC07 Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 44
TCGA-E2-A1IN Cancer tissue TBC08 Positive Positive Negative Infiltrating Ductal Carcinoma I 60
TCGA-BH-A0HX Cancer tissue TBC09 Positive Positive Negative Infiltrating Ductal Carcinoma IIB 54
TCGA-E9-A5FL Cancer tissue TBC10 Negative Negative Negative Metaplastic Carcinoma IIB 65
TCGA-AR-A24T Cancer tissue TBC11 Positive Positive Negative Infiltrating Lobular Carcinoma IIIC 46
TCGA-BH-A1EN Cancer tissue TBC12 Negative Negative Positive Other  specify IIA 78
TCGA-BH-A0AU Cancer tissue TBC13 Positive Positive Positive Infiltrating Ductal Carcinoma IIA 45
TCGA-A2-A0CR Cancer tissue TBC14 Positive Positive Negative Infiltrating Lobular Carcinoma IIB 54
TCGA-BH-A0DI Cancer tissue TBC15 Positive Positive Negative Infiltrating Ductal Carcinoma IIB 63
TCGA-A2-A0YD Cancer tissue TBC16 Positive Positive Negative Infiltrating Lobular Carcinoma IIB 63  
TCGA-A1-A0SQ Cancer tissue TBC17 Positive Positive Negative Infiltrating Ductal Carcinoma IIB 45
TCGA-EW-A1J6 Cancer tissue TBC18 Positive Positive Negative Infiltrating Ductal Carcinoma I 70
TCGA-S3-AA14 Cancer tissue TBC19 Positive Positive Positive Infiltrating Ductal Carcinoma I 47
TCGA-A7-A26G Cancer tissue TBC20 Negative Negative Negative Other  specify IIA 50
TCGA-A2-A3XY Cancer tissue TBC21 Negative Negative Negative Infiltrating Ductal Carcinoma IIB 49
TCGA-A7-A4SE Cancer tissue TBC22 Negative Negative Negative Infiltrating Ductal Carcinoma IIA 54
TCGA-BH-A0AW Cancer tissue TBC23 Positive Negative Positive Infiltrating Ductal Carcinoma IIA 56
TCGA-D8-A1JC Cancer tissue TBC24 Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 59
TCGA-E2-A1IJ Cancer tissue TBC25 Positive Positive Negative Infiltrating Lobular Carcinoma I 57
TCGA-D8-A1XF Cancer tissue TBC26 Positive Positive Negative Infiltrating Ductal Carcinoma IIA 45
TCGA-EW-A2FR Cancer tissue TBC27 Negative Negative Positive Infiltrating Ductal Carcinoma IIIC 59
TCGA-BH-A1FB Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIB 60
TCGA-E2-A15K Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIA 58
TCGA-BH-A0DV Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 54
TCGA-BH-A0AY Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIA 62
TCGA-BH-A0AZ Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIIA 47
TCGA-BH-A0BV Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIB 78
TCGA-BH-A0BA Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Mixed Histology IIIC 51
TCGA-BH-A1ES Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIB 35
TCGA-E9-A1RD Non-cancerousmammary tissue
Not
appricable Unknown Unknown Unknown Infiltrating Ductal Carcinoma IIA 67
TCGA-E9-A1NA Non-cancerousmammary tissue
Not
appricable Positive Positive Positive Mixed Histology IIA 58
TCGA-BH-A1FN Non-cancerousmammary tissue
Not
appricable Positive Positive Unknown Infiltrating Ductal Carcinoma IIA 34
TCGA-E2-A1B5 Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Lobular Carcinoma IIA 46
TCGA-AC-A2FB Non-cancerousmammary tissue
Not
appricable Positive Positive Positive Infiltrating Lobular Carcinoma IIA 65
TCGA-BH-A0DH Non-cancerousmammary tissue
Not
appricable Positive Positive Negative Infiltrating Ductal Carcinoma IIB 63
TCGA-E9-A1RD Non-cancerousmammary tissue
Not
appricable Unknown Unknown Unknown Infiltrating Ductal Carcinoma IIA 67
Supplementary Table 2. Data of breast cancer tissues and non-cancerous mammary tissues downloaded from the TCGA database
No. Gene symbol Chr Nt number Probe ID Relation to a CpGisland Position to a TSS
No. of
consecutive
probe
Incidence of
methylation in
cancer cell lines
Incidence of methylation
in cancer tissues
Copy number
alterations*
1 C1orf50 1 42785402 cg27232866 Island 18109;18095 2 17 22 None
42785582 cg19254906 S Shore 18289;18275 2 16 21
1a - 1 63319650 cg15617155 Island - 2 17 26 None
63319873 cg02283366 Island - 2 17 22
2 SYCN 19 39204069 cg22290648 Island 198 2 16 22 None
39204191 cg02863073 Island 76 2 16 22
2a - 19 43699597 cg08669447 Island - 2 16 24 None
43699761 cg09489306 Island - 2 16 23
2b - 21 36693224 cg00495860 Island - 2 18 26 None
36693747 cg10445315 Island - 2 19 22
3 NKX2-6 8 23706412 cg14428146 Island 187;-730 2 17 21 None
23706457 cg15854847 Island 142;-685 2 16 21
4 CCDC181 1 169427397 cg00100121 Island 78;21;66;78;33273 3 13 23 None
169427399 cg13958426 Island 76;19;64;76;33271 3 12 23
169427468 cg00002719 Island 7;-50;-5;7;33202 3 12 21
169427474 cg08104202 Island 1;-56;-11;1;33196 3 12 22
169427547 cg23818870 Island -72;-129;-84;-72;33123 3 11 24
169427596 cg16998150 Island -121;-178;-133;-121;33074 3 9 23
169427620 cg08047907 Island -145;-202;-157;-145;33050 3 11 24
169427630 cg24808280 Island -155;-212;-167;-155;33040 3 13 24
5 HIST3H2BA 1 228464777 cg26911220 Island -150 3 14 24 Gain
228464827 cg07726139 Island -200 3 14 26
228464880 cg13799227 S Shore -253 3 11 22
6 MIR129-2 11 43581295 cg15556502 Island 24858;2405;1799;-86 3 12 21 None
43581297 cg14416371 Island 24860;2407;1801;-84 3 12 24
43581307 cg14944647 Island 24870;2417;1811;-74 3 12 23
43581329 cg01939477 Island 24892;2439;1833;-52 3 12 23
43581364 cg16407471 Island 24927;2474;1868;-17 3 11 23
43581370 cg05376374 Island 24933;2480;1874;-11 3 11 22
7 PHOX2A 11 72244357 cg05093169 Island -180;1308 3 13 26 None
72244395 cg16922279 Island -218;1270 3 13 22
72244503 cg08876932 Island -326;1162 3 13 22
72244555 cg24530250 Island -378;1110 3 12 23
8 RP11-445F12.1 17 36934600 cg13677415 Island 2053;2059;2062;2023 3 9 23 None
36934624 cg16364121 Island 2029;2035;2038;1999 3 13 22
36934859 cg23402821 Island 1794;1800;1803;1764 3 10 21
9 AC079154.1 2 124024684 cg03696599 Island 490;-604;-604 3 11 24 None
124024686 cg13358636 Island 488;-602;-602 3 14 24
124025009 cg18582824 Island 165;-279;-279 3 13 22
10 GYPC 2 126656532 cg19484420 Island 598;596;347;389;342;398 3 11 21 None
126656805 cg17848763 S_Shore 871;869;620;662;615;671 3 10 23
126656879 cg13901526 S_Shore 945;943;694;736;689;745 3 9 21
10a - 3 171028418 cg07139301 Island - 3 9 22 None
171028476 cg14777768 Island - 3 11 25
171028502 cg25203962 Island - 3 11 25
11 CDO1 5 115816723 cg02792792 Island 232;-65;-65 3 10 24 None
115816734 cg14470895 Island 221;-76;-76 3 10 23
115816788 cg23180938 Island 167;-130;-130 3 14 22
12 SIM1 6 100465030 cg21684012 Island -1352;-100;-140 3 12 22 None
100465064 cg27252696 Island -1386;-134;-174 3 12 22
100465070 cg17380661 Island -1392;-140;-180 3 12 22
*According to a study with reference number [23].
Supplementary Table 3. Twelve genes from 16 genomic regions specifically methylated in breast cancer cells
Genomic location was based upon human genome assembly hg38.
Gene symbol Primer Primer sequence Length(bp)
Annealing
Temprature (°C)
Sequencing
primer
Sequencing primer
sequence Sequencing to analyze
SYCN Forward GGGTTTTAGATTTAGGTTAGGTAGGT 284 54 Forward TTAGTGTTTTGAGTTTAGGG YGTTTGTTTYGTTTT
Reverse CCCAACAATTCTCATAATAAAAATC-Biotine
MIR129-2 Forward GGAGATAGAGGGATAGGATAGGTAG 274 54 Forward AGGAGTGGTGAGATTGA GTYGYGATGGAAYGYGTTGGGGAGATTTAG
Reverse ACCCTAAAACCAAACAAACTAAATC-Biotine
SIM1 Forward Biotine-GGTTTAGAGGGTAGTAAGATTTAGAGTT 334 54 Reverse ACCAATAAAACTAAATAACA CRAATCRACCCCRAACC
Reverse AACTACCCCCCCTAACTTCTTTATA
CCDC181 Forward GAAGAGAGATAGTTATAAGAGGGAAATTTT 453 54 Forward GGGAAATTTTATAATTAATA
 
TAGYGGTATTTYGYGAGTT
TTTATAA
Reverse ACCCTCTATCCCACCATTAACATCT-Biotine
Supplementary Table 4. Conditions for bisulfite pyrosequencing
Genomic location was based upon human genome assembly hg38.
Probes on autosomes and sex chromosomes 477,344 probes
Peripheral leucocyte samples
Non-cancerous mammary tissues
3-consecutive-
probe approach
2-consecutive-
probe approach
136,830
475
Consecutive probes
Genomic regions
Genes
12
6
3
5,698
Probes unmethylated in
non-cancerous mammary cells
Figure 1
Cancer cell lines
Cancer tissues
Human mammary epithelial cells 
333
93
195,397
153,235
(β ≤ 0.2)
(3 of 3)
(15 of 15)
(1 of 1)
Probes methylated in  
breast cancer cells
β ≥ 0.8
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